AstraZeneca PLC / Bristol-Myers Squibb diabetes alliance assets

Type 2 Diabetes Mellitus

Disease Overview

Type 2 diabetes is a chronic metabolic disorder marked by insulin resistance and progressive beta-cell dysfunction, accounting for ~90-95% of diabetes diagnoses. Treatment ladders from metformin through second-line orals (DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas) and injectables (GLP-1 agonists, basal/prandial insulin). The 2013-14 era saw the SGLT-2 class emerge and CV outcomes trials (CVOTs) become mandatory under FDA 2008 guidance.

Competitive Landscape

The diabetes franchise AZ acquired sat in the second-line oral and injectable spaces. In DPP-4 inhibitors, Onglyza (saxagliptin) competed against market-leader Januvia (Merck, ~$5-6B peak sales), Tradjenta (BI/Lilly), and Nesina (Takeda) — and Onglyza had been wounded by SAVOR-TIMI-53 (2013), which showed no CV superiority and a heart-failure signal that ultimately capped its trajectory. In the emerging SGLT-2 class, Farxiga (dapagliflozin) competed against first-mover Invokana (J&J, approved Mar 2013) and Jardiance (BI/Lilly, approved Aug 2014); $600M of the $1.4B in milestones was tied to Farxiga's January 2014 US approval. In GLP-1, Byetta and Bydureon (exenatide / extended-release exenatide) competed against Victoza (Novo Nordisk, the share leader), and Symlin (pramlintide) was a small amylin-analog adjunct to insulin. Panmure Gordon called the deal 'sensible'; Citi's Andrew Baum called it 'win-win' — letting BMS pivot to immuno-oncology while AZ doubled down on cardiometabolic. The deal proved foundational for AZ's eventual cardiometabolic franchise (Farxiga later became a multi-billion-dollar SGLT-2 with HF and CKD label expansions, validating the long-term royalty/milestone structure through 2025).